-+ 0.00%
-+ 0.00%
-+ 0.00%

BioVersys' AlpE regimen shows early antibacterial activity in Phase 2a tuberculosis trial

PUBT·11/20/2026 06:00:55
Listen to the news
BioVersys' AlpE regimen shows early antibacterial activity in Phase 2a tuberculosis trial
  • BioVersys reported Phase 2a ENABLE results supporting further development of its AlpE tuberculosis treatment, developed with GSK.
  • AlpE combined with RZE showed antibacterial activity comparable to standard treatment, although the trial was not designed for formal comparisons.
  • All tested regimens showed antibacterial activity; AlpE was generally well tolerated over 14 days in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.
  • Results were already presented at the Union World Conference on Lung Health, held November 17-20, 2026, in Rio de Janeiro.
  • A separate Phase 2b trial is evaluating AlpE-RZE during the first two months of treatment; a Phase 2 meningitis program is advancing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioversys AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2438912_en) on November 20, 2026, and is solely responsible for the information contained therein.